Filing Details
- Accession Number:
- 0001209191-16-095840
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-02-04 18:51:22
- Reporting Period:
- 2016-02-02
- Filing Date:
- 2016-02-04
- Accepted Time:
- 2016-02-04 18:51:22
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp\Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-02-02 | 17,299 | $0.01 | 121,763 | No | 4 | A | Direct | |
Common Stock | Disposition | 2016-02-03 | 2,597 | $89.92 | 119,166 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-02-03 | 2,100 | $90.98 | 117,066 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-02-03 | 700 | $91.89 | 116,366 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-02-03 | 645 | $92.80 | 115,721 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2016-02-02 | 34,482 | $0.00 | 34,482 | $91.05 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
34,482 | 2026-02-01 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $89.92 (range $89.31 to $90.27).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $90.98 (range $90.38 to $91.32).
- Open market sales reported on this line occurred at a weighted average price of $91.89 (range $91.38 to $92.35).
- Open market sales reported on this line occurred at a weighted average price of $92.80 (range $92.40 to $93.03).
- The option vests in 16 quarterly installments from 02/02/2016.